Eton Pharmaceuticals/$ETON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eton Pharmaceuticals
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Ticker
$ETON
Sector
Primary listing
Employees
31
Headquarters
Website
ETON Metrics
BasicAdvanced
$474M
-
-$0.16
1.13
-
Price and volume
Market cap
$474M
Beta
1.13
52-week high
$21.48
52-week low
$5.35
Average daily volume
281K
Financial strength
Current ratio
1.773
Quick ratio
1.032
Long term debt to equity
116.443
Total debt to equity
128.096
Interest coverage (TTM)
0.50%
Profitability
EBITDA (TTM)
4.538
Gross margin (TTM)
63.44%
Net profit margin (TTM)
-7.10%
Operating margin (TTM)
3.36%
Effective tax rate (TTM)
-2.51%
Revenue per employee (TTM)
$1,880,000
Management effectiveness
Return on assets (TTM)
1.83%
Return on equity (TTM)
-22.06%
Valuation
Price to revenue (TTM)
8.039
Price to book
19.79
Price to tangible book (TTM)
-53.17
Price to free cash flow (TTM)
113.965
Free cash flow yield (TTM)
0.88%
Free cash flow per share (TTM)
0.155
Growth
Revenue change (TTM)
85.40%
Earnings per share change (TTM)
-39.91%
3-year revenue growth (CAGR)
52.51%
3-year earnings per share growth (CAGR)
-31.36%
What the Analysts think about ETON
Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.
Bulls say / Bears say
Eton delivered Q2 2025 product sales of $18.9 million, up 108% year-over-year, marking its 18th consecutive quarter of sequential product sales growth driven by strong performance of ALKINDI SPRINKLE, INCRELEX, and GALZIN (GlobeNewswire).
The FDA approved KHINDIVI™ (hydrocortisone) Oral Solution on May 28, 2025—the first and only FDA-approved hydrocortisone oral solution—with a launch in early June and combined peak sales of KHINDIVI and ALKINDI SPRINKLE expected to exceed $50 million (GlobeNewswire).
Eton’s pipeline advanced as the FDA accepted the NDA for ET-600 (desmopressin oral solution) on July 8, 2025 with a PDUFA target action date of February 25, 2026, positioning ET-600 to become the only oral liquid desmopressin option if approved (GlobeNewswire).
Despite strong product sales growth, Eton reported a GAAP loss with Q2 2025 EPS of −$0.10 and Q1 2025 EPS of −$0.06, underscoring that the company remains unprofitable on a GAAP basis (GlobeNewswire) (GlobeNewswire).
Eton’s lead pipeline candidate ET-600 targets central diabetes insipidus in only ~3,000 U.S. pediatric patients, highlighting the ultra-rare nature of its addressable market and capping revenue potential (GlobeNewswire).
The company’s growth hinges on future regulatory milestones, with ET-600’s FDA PDUFA action date set for February 25, 2026 and a KHINDIVI age‐expansion supplement not expected until H1 2026, exposing Eton to potential approval delays that could postpone revenue accrual (GlobeNewswire) (BioSpace).
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
ETON Financial Performance
Revenues and expenses
ETON Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eton Pharmaceuticals stock?
Eton Pharmaceuticals (ETON) has a market cap of $474M as of September 18, 2025.
What is the P/E ratio for Eton Pharmaceuticals stock?
The price to earnings (P/E) ratio for Eton Pharmaceuticals (ETON) stock is 0 as of September 18, 2025.
Does Eton Pharmaceuticals stock pay dividends?
No, Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Eton Pharmaceuticals dividend payment date?
Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders.
What is the beta indicator for Eton Pharmaceuticals?
Eton Pharmaceuticals (ETON) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.